CO2024002786A2 - Métodos y composiciones para tratar el cáncer - Google Patents

Métodos y composiciones para tratar el cáncer

Info

Publication number
CO2024002786A2
CO2024002786A2 CONC2024/0002786A CO2024002786A CO2024002786A2 CO 2024002786 A2 CO2024002786 A2 CO 2024002786A2 CO 2024002786 A CO2024002786 A CO 2024002786A CO 2024002786 A2 CO2024002786 A2 CO 2024002786A2
Authority
CO
Colombia
Prior art keywords
compositions
methods
treating cancer
scc
treating
Prior art date
Application number
CONC2024/0002786A
Other languages
English (en)
Spanish (es)
Inventor
Steven Fruchtman
Matthew Parris
Original Assignee
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconova Therapeutics Inc filed Critical Onconova Therapeutics Inc
Publication of CO2024002786A2 publication Critical patent/CO2024002786A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2024/0002786A 2021-08-12 2024-03-06 Métodos y composiciones para tratar el cáncer CO2024002786A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163232409P 2021-08-12 2021-08-12
PCT/US2022/040092 WO2023018891A1 (en) 2021-08-12 2022-08-11 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
CO2024002786A2 true CO2024002786A2 (es) 2024-03-18

Family

ID=85200519

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0002786A CO2024002786A2 (es) 2021-08-12 2024-03-06 Métodos y composiciones para tratar el cáncer

Country Status (11)

Country Link
US (1) US20240299326A1 (https=)
EP (1) EP4384498A1 (https=)
JP (1) JP2024531238A (https=)
CN (1) CN118076583A (https=)
AU (1) AU2022326485A1 (https=)
CA (1) CA3228644A1 (https=)
CO (1) CO2024002786A2 (https=)
GB (1) GB2628229A (https=)
IL (1) IL310759A (https=)
MX (1) MX2024001935A (https=)
WO (1) WO2023018891A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5156389B2 (ja) * 2005-01-05 2013-03-06 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 薬剤耐性増殖性疾患の治療剤
WO2014089483A1 (en) * 2012-12-07 2014-06-12 Onconova Therapeutics, Inc. Methods and compositions for treatment of cancer
JP2018530590A (ja) * 2015-10-14 2018-10-18 タリックス ファーマシューティカルズ リミテッド 表皮水疱症の処置のための方法及び組成物
CA3076610A1 (en) * 2017-09-22 2019-03-28 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa

Also Published As

Publication number Publication date
WO2023018891A1 (en) 2023-02-16
US20240299326A1 (en) 2024-09-12
GB2628229A (en) 2024-09-18
AU2022326485A1 (en) 2024-02-29
MX2024001935A (es) 2024-03-21
GB202402730D0 (en) 2024-04-10
CA3228644A1 (en) 2023-02-16
CN118076583A (zh) 2024-05-24
WO2023018891A8 (en) 2023-09-21
IL310759A (en) 2024-04-01
JP2024531238A (ja) 2024-08-29
EP4384498A1 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
CO2021010415A2 (es) Inhibidor jak y método de preparación del mismo
PY2146661A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
FI3849534T3 (fi) Yhdistelmähoidot
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MX2025000105A (es) Inhibidor de kras g12c para el tratamiento del cancer
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
MX2023003332A (es) Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades.
MX2021013980A (es) Compuesto para el tratamiento de gota o hiperuricemia.
IL314873A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
ECSP18051143A (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
AR114216A1 (es) Composiciones oftálmicas de compuestos de bencimidazol para uso único diario
JP2016502981A5 (https=)
WO2006083979B1 (en) Local treatment of neurofibromas
CO2024002786A2 (es) Métodos y composiciones para tratar el cáncer
AU2017261303A1 (en) Ophthalmic compositions
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX2023011176A (es) Tratamiento de hidradenitis supurativa con orismilast.
MX2020010201A (es) Conjugado de farmaco citotoxico y forma de profarmaco de dicho conjugado.
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
BR112019005224A2 (pt) forma de dosagem para alívio prolongado
EA202092579A1 (ru) Оксозамещенное соединение
AR129959A1 (es) Método para tratar enfermedades o trastornos orgánicos con inhibidores de ask1
EP4069251A4 (en) SALTS AND POLYMORPHS OF CETHROMYCIN FOR THE TREATMENT OF DISEASES